News - Swedish Orphan Biovitrum, Rare diseases

Filter

Popular Filters

SOBI files for Orfadin oral suspension with EMA

22-08-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning (August 22) that the company's application for…

EuropeOrfadinPharmaceuticalRare diseasesRegulationSwedish Orphan Biovitrum

Auxilium and SOBI collaborate on Xiapex

16-07-2013

USA-based Auxilium Pharmaceuticals (Nasdaq: AUXL) and Swedish Orphan Biovitrum (STO: SOBI) have entered…

Auxilium PharmaceuticalsEuropeLicensingPharmaceuticalRare diseasesRest of the WorldSwedish Orphan BiovitrumXiapex

Positive Ph III results for Biogen Idec and SOBI's hemophilia B agent

27-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) and partner Swedish Orphan Biovitrum (STO: SOBI) have announced…

Biogen IdecBiotechnologyEuropeNorth AmericaPharmaceuticalRare diseasesRegulationResearchrFIXFcSobiSwedish Orphan Biovitrum

Pharming extends Ruconest deal with SOBI

16-08-2011

Netherlands-based biotech firm Pharming Group NV (Euronext: PHARM) has extended its existing agreement…

BiotechnologyEuropeLicensingPharmaceuticalPharmingRare diseasesRest of the WorldRhucinRuconestSwedish Orphan Biovitrum

Back to top